Celldex Therapeutics (CLDX) Interest Expenses (2010 - 2013)
Celldex Therapeutics (CLDX) posted quarterly Interest Expenses of $364000.0 for Q1 2026, up 120.61% year-over-year from $165000.0 in Q1 2025, and up 9000.0% quarter-over-quarter from $4000.0 in Q4 2025.
Powered by 
Analysis
Celldex Therapeutics (CLDX) Interest Expenses (2010 - 2013) Analysis & Trends
Celldex Therapeutics' Interest Expenses history runs 16 years deep, the most recent figure standing at $364000.0 for Q1 2026.
- In Q1 2026, Interest Expenses rose 120.61% year-over-year to $364000.0; the TTM figure through Mar 2026 stood at $364000.0 (up 120.61% YoY), while the FY2025 annual figure was $374.5 million, up 17.12% from the prior year.
- Interest Expenses for Q1 2026 stood at $364000.0, up from $4000.0 in the prior quarter.
- The five-year high for Interest Expenses was $347.4 million in Q4 2023, with the low at $3000.0 in Q3 2025.
- The 5-year median for Interest Expenses is $532000.0 (2023), against an average of $58.3 million.
- The sharpest annual moves came in 2022 and 2025: Interest Expenses jumped 4198.41% in 2022, then plunged 100.0% in 2025.
- Celldex Therapeutics' Interest Expenses stood at $312.8 million in 2022, then gained by 11.07% to $347.4 million in 2023, then dropped by 7.95% to $319.8 million in 2024, then slumped by 100.0% to $4000.0 in 2025, then soared by 9000.0% to $364000.0 in 2026.
- Business Quant data shows CLDX's Interest Expenses at $364000.0 in Q1 2026, $4000.0 in Q4 2025, and $3000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | -1.00 Mn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | 23.78 Mn |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 39.74 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 93.62 Mn |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Celldex Therapeutics | 3.07 Bn | 3.07 Bn | -2.57 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2013 | 85,000.00 |
| Sep 30, 2013 | 13,000.00 |
| Jun 30, 2013 | 519,000.00 |
| Mar 31, 2013 | 310,000.00 |
| Dec 31, 2012 | 351,000.00 |
| Sep 30, 2012 | 381,000.00 |
| Jun 30, 2012 | 411,000.00 |
| Mar 31, 2012 | 433,000.00 |
| Dec 31, 2011 | 438,000.00 |
| Sep 30, 2011 | 438,000.00 |
| Jun 30, 2011 | 434,000.00 |
| Mar 31, 2011 | 485,000.00 |
| Dec 31, 2010 | 335,000.00 |
| Sep 30, 2010 | 332,000.00 |
| Jun 30, 2010 | 334,000.00 |